|
1
|
Penna A and Buchanan N: Paracetamol
poisoning in children and hepatotoxicity. Br J Clin Pharmacol.
32:143–149. 1991.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kurtovic J and Riordan S:
Paracetamol-induced hepatotoxicity at recommended dosage. J Intern
Med. 253:240–243. 2003.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Morthorst BR, Erlangsen A, Nordentoft M,
Hawton K, Hoegberg LCG and Dalhoff KP: Availability of paracetamol
sold over the counter in Europe: A descriptive cross-sectional
international survey of pack size restriction. Basic Clin Pharmacol
Toxicol. 122:643–649. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Steventon GB, Mitchell SC and Waring RH:
Human metabolism of paracetamol (acetaminophen) at different dose
levels. Drug Metabol Drug Interact. 13:111–117. 1996.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Jollow DJ, Mitchell JR, Potter WZ, Davis
DC, Gillette JR and Brodie BB: Acetaminophen-induced hepatic
necrosis. II. Role of covalent binding in vivo. J Pharmacol Exp
Ther. 187:195–202. 1973.PubMed/NCBI
|
|
6
|
Nilsson JLÅ, Blomgren A, Nilsson UJ,
Högestätt ED and Grundemar L:
N,N'-Bis(2-mercaptoethyl)isophthalamide binds electrophilic
paracetamol metabolites and prevents paracetamol-induced liver
toxicity. Basic Clin Pharmacol Toxicol. 123:589–593.
2018.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Yayla M, Halici Z, Unal B, Bayir Y,
Akpinar E and Gocer F: Protective effect of Et-1 receptor
antagonist bosentan on paracetamol induced acute liver toxicity in
rats. Eur J Pharmacol. 726:87–95. 2014.PubMed/NCBI View Article : Google Scholar
|
|
8
|
El-Demerdash E, Salam OM, El-Batran SA,
Abdallah HM and Shaffie NM: Inhibition of the renin-angiotensin
system attenuates the development of liver fibrosis and oxidative
stress in rats. Clin Exp Pharmacol Physiol. 35:159–167.
2008.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Stokkeland K, Lageborn CT, Ekbom A, Höijer
J, Bottai M, Stål P and Söderberg-Löfdal K: Statins and
angiotensin-converting enzyme inhibitors are associated with
reduced mortality and morbidity in chronic liver disease. Basic
Clin Pharmacol Toxicol. 122:104–110. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Aroor AR, Demarco VG, Jia G, Sun Z,
Nistala R, Meininger GA and Sowers JR: The role of tissue
renin-angiotensin-aldosterone system in the development of
endothelial dysfunction and arterial stiffness. Front Endocrinol
(Lausanne). 4(161)2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Bataller R, Gäbele E, Schoonhoven R,
Morris T, Lehnert M, Yang L, Brenner DA and Rippe RA: Prolonged
infusion of angiotensin II into normal rats induces stellate cell
activation and proinflammatory events in liver. Am J Physiol.
285:G642–G651. 2003.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bataller R, Gäbele E, Parsons CJ, Morris
T, Yang L, Schoonhoven R, Brenner DA and Rippe RA: Systemic
infusion of angiotensin II exacerbates liver fibrosis in bile
duct-ligated rats. Hepatology. 41:1046–1055. 2005.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Friedman SL: Mechanisms of hepatic
fibrogenesis. Gastroenterology. 134:1655–1669. 2008.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Mollnau H, Wendt M, Szöcs K, Lassègue B,
Schulz E, Oelze M, Li H, Bodenschatz M, August M, Kleschyov AL, et
al: Effects of angiotensin II infusion on the expression and
function of NAD(P)H oxidase and components of nitric oxide/cGMP
signaling. Circ Res. 90:E58–E65. 2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Landmesser U, Spiekermann S, Preuss C,
Sorrentino S, Fischer D, Manes C, Mueller M and Drexler H:
Angiotensin II induces endothelial xanthine oxidase activation:
Role for endothelial dysfunction in patients with coronary disease.
Arterioscler Thromb Vasc Biol. 27:943–948. 2007.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Bataller R, Ginès P, Nicolás JM, Görbig
MN, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V and Rodés J:
Angiotensin II induces contraction and proliferation of human
hepatic stellate cells. Gastroenterology. 118:1149–1156.
2000.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hitomi H, Kiyomoto H and Nishiyama A:
Angiotensin II and oxidative stress. Curr Opin Cardiol. 22:311–315.
2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yeung JH: Effect of sulphydryl drugs on
paracetamol-induced hepatotoxicity in mice. Drug Metabol Drug
Interact. 6:295–301. 1988.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Karcioglu SS, Palabiyik SS, Bayir Y,
Karakus E, Mercantepe T, Halici Z and Albayrak A: The role of RAAS
inhibition by aliskiren on paracetamol-induced hepatotoxicity model
in rats. J Cell Biochem. 117:638–646. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
McDowell G, Coutie W, Shaw C, Buchanan KD,
Struthers AD and Nicholls DP: The effect of the neutral
endopeptidase inhibitor drug, candoxatril, on circulating levels of
two of the most potent vasoactive peptides. Br J Clin Pharmacol.
43:329–332. 1997.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mangiafico S, Costello-Boerrigter LC,
Andersen IA, Cataliotti A and Burnett JC Jr: Neutral endopeptidase
inhibition and the natriuretic peptide system: An evolving strategy
in cardiovascular therapeutics. Eur Heart J. 34:886–893c.
2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gerwig T, Meissner H, Bilzer M, Kiemer AK,
Arnholdt H, Vollmar AM and Gerbes AL: Atrial natriuretic peptide
preconditioning protects against hepatic preservation injury by
attenuating necrotic and apoptotic cell death. J Hepatol.
39:341–348. 2003.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kiemer AK, Gerbes AL, Bilzer M and Vollmar
AM: The atrial natriuretic peptide and cGMP: Novel activators of
the heat shock response in rat livers. Hepatology. 35:88–94.
2002.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Sekino M, Makita T, Ureshino H, Sungsam C
and Sumikawa K: Synthetic atrial natriuretic peptide improves
systemic and splanchnic circulation and has a lung-protective
effect during endotoxemia in pigs. Anesth Analg. 110:141–147.
2010.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kostis JB, Packer M, Black HR, Schmieder
R, Henry D and Levy E: Omapatrilat and enalapril in patients with
hypertension: The omapatrilat cardiovascular treatment vs enalapril
(OCTAVE) trial. Am J Hypertens. 17:103–111. 2004.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Quaschning T, d'Uscio LV, Shaw S and
Lüscher TF: Vasopeptidase inhibition exhibits endothelial
protection in salt-induced hypertension. Hypertension.
37:1108–1113. 2001.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Dong Y, Zhou H, Shaffer E, Atamas N, Liao
WC and Wei C: The cardiovascular actions of omapatrilat in
spontaneously hypertensive rats. Curr Hypertens Rep. 3 (Suppl
2):S1–S5. 2001.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Taal MW, Nenov VD, Wong W, Satyal SR,
Sakharova O, Choi JH, Troy JL and Brenner BM: Vasopeptidase
inhibition affords greater renoprotection than
angiotensin-converting enzyme inhibition alone. J Am Soc Nephrol.
12:2051–2059. 2001.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Song Z, Cui Y, Ding MZ, Jin HX and Gao Y:
Protective effects of recombinant human brain natriuretic peptide
against LPS-Induced acute lung injury in dogs. Int Immunopharmacol.
17:508–512. 2013.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Kostakoglu U, Topcu A, Atak M, Tumkaya L,
Mercantepe T and Uydu HA: The protective effects of
angiotensin-converting enzyme inhibitor against cecal ligation and
puncture-induced sepsis via oxidative stress and inflammation. Life
Sci. 241(117051)2020.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ugan RA, Un H, Gurbuz MA, Kaya G,
Kahramanlar A, Aksakalli-Magden ZB, Halici Z and Cadirci E:
Possible contribution of the neprilysin/ACE pathway to sepsis in
mice. Life Sci. 258(118177)2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Hayek T, Hamoud S, Keidar S, Pavlotzky E,
Coleman R, Aviram M and Kaplan M: Omapatrilat decreased macrophage
oxidative status and atherosclerosis progression in atherosclerotic
apolipoprotein E-deficient mice. J Cardiovasc Pharmacol.
43:140–147. 2004.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lapointe N, Nguyen QT, Desjardins JF,
Marcotte F, Pourdjabbar A, Moe G, Calderone A and Rouleau JL:
Effects of pre-, peri-, and postmyocardial infarction treatment
with omapatrilat in rats: Survival, arrhythmias, ventricular
function, and remodeling. Am J Physiol Heart Circ Physiol.
285:H398–H405. 2003.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Canayakin D, Bayir Y, Baygutalp NK,
Karaoglan ES, Atmaca HT, Ozgeris FBK, Keles MS and Halici Z:
Paracetamol-induced nephrotoxicity and oxidative stress in rats:
The protective role of Nigella sativa. Pharm Biol. 54:2082–2091.
2016.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Randle LE, Sathish JG, Kitteringham NR,
Macdonald I, Williams DP and Park BK: alpha(1)-Adrenoceptor
antagonists prevent paracetamol-induced hepatotoxicity in mice. Br
J Pharmacol. 153:820–830. 2008.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Patterson AD, Shah YM, Matsubara T, Krausz
KW and Gonzalez FJ: Peroxisome proliferator-activated receptor
alpha induction of uncoupling protein 2 protects against
acetaminophen-induced liver toxicity. Hepatology. 56:281–290.
2012.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Scialis RJ, Ghanem CI and Manautou JE: The
modulation of transcriptional expression and inhibition of
multidrug resistance associated protein 4 (MRP4) by analgesics and
their primary metabolites. Curr Res Toxicol. 1:34–41.
2020.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Palabiyik SS, Karakus E, Akpinar E, Halici
Z, Bayir Y, Yayla M and Kose D: The role of urotensin receptors in
the paracetamol-induced hepatotoxicity model in mice: Ameliorative
potential of urotensin II antagonist. Basic Clin Pharmacol Toxicol.
118:150–159. 2016.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Ferah I, Halici Z, Bayir Y, Demirci E,
Unal B and Cadirci E: The role of infliximab on paracetamol-induced
hepatotoxicity in rats. Immunopharmacol Immunotoxicol. 35:373–381.
2013.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Sun Y, Oberley LW and Li Y: A simple
method for clinical assay of superoxide dismutase. Clin Chem.
34:497–500. 1988.PubMed/NCBI
|
|
41
|
Ohkawa H, Ohishi N and Yagi K: Assay for
lipid peroxides in animal tissues by thiobarbituric acid reaction.
Anal Biochem. 95:351–358. 1979.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Ugan RA, Cadirci E, Halici Z, Toktay E and
Cinar I: The role of urotensin-II and its receptors in
sepsis-induced lung injury under diabetic conditions. Eur J
Pharmacol. 818:457–469. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Cigremis Y, Turel H, Adiguzel K, Akgoz M,
Kart A, Karaman M and Ozen H: The effects of acute acetaminophen
toxicity on hepatic mRNA expression of SOD, CAT, GSH-Px, and levels
of peroxynitrite, nitric oxide, reduced glutathione, and
malondialdehyde in rabbit. Mol Cell Biochem. 323:31–38.
2009.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Betto MRB, Lazarotto LF, Watanabe TT,
Driemeier D, Leite CE and Campos MM: Effects of treatment with
enalapril on hepatotoxicity induced by acetaminophen in mice.
Naunyn Schmiedebergs Arch Pharmacol. 385:933–943. 2012.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Bessems JG and Vermeulen NP: Paracetamol
(acetaminophen)-induced toxicity: Molecular and biochemical
mechanisms, analogues and protective approaches. Crit Rev Toxicol.
31:55–138. 2001.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Karatas E, Bayraktutan Z and Cadirci E:
Investigation of the effects of amlodipine on paracetamol-induced
acute kidney toxicity in rats. Clin Exp Health Sci. 12:155–161.
2022.
|
|
47
|
Kalsi SS, Dargan PI, Waring WS and Wood
DM: A review of the evidence concerning hepatic glutathione
depletion and susceptibility to hepatotoxicity after paracetamol
overdose. Open Access Emerg Med. 3:87–96. 2011.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Castañeda-Arriaga R, Pérez-González A
and Galano A: Chemical protectors against the toxic effects of
paracetamol (acetaminophen) and its meta analogue: Preventing
protein arylation. ACS Omega. 3:18582–18591. 2018.
|
|
49
|
Ip SP, Kwan PC, Williams CH, Pang S,
Hooper NM and Leung PS: Changes of angiotensin-converting enzyme
activity in the pancreas of chronic hypoxia and acute pancreatitis.
Int J Biochem Cell Biol. 35:944–954. 2003.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Hoshida S, Kato J, Nishino M, Egami Y,
Takeda T, Kawabata M, Tanouchi J, Yamada Y and Kamada T: Increased
angiotensin-converting enzyme activity in coronary artery specimens
from patients with acute coronary syndrome. Circulation.
103:630–633. 2001.PubMed/NCBI View Article : Google Scholar
|
